1. Home
  2. OXLC vs DNTH Comparison

OXLC vs DNTH Comparison

Compare OXLC & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OXLC
  • DNTH
  • Stock Information
  • Founded
  • OXLC 2010
  • DNTH 2015
  • Country
  • OXLC United States
  • DNTH United States
  • Employees
  • OXLC N/A
  • DNTH N/A
  • Industry
  • OXLC Investment Managers
  • DNTH Biotechnology: Pharmaceutical Preparations
  • Sector
  • OXLC Finance
  • DNTH Health Care
  • Exchange
  • OXLC Nasdaq
  • DNTH Nasdaq
  • Market Cap
  • OXLC 1.7B
  • DNTH 1.4B
  • IPO Year
  • OXLC N/A
  • DNTH N/A
  • Fundamental
  • Price
  • OXLC $15.16
  • DNTH $38.40
  • Analyst Decision
  • OXLC Strong Buy
  • DNTH Strong Buy
  • Analyst Count
  • OXLC 1
  • DNTH 10
  • Target Price
  • OXLC $6.00
  • DNTH $68.00
  • AVG Volume (30 Days)
  • OXLC 1.9M
  • DNTH 485.3K
  • Earning Date
  • OXLC 11-01-2023
  • DNTH 11-05-2025
  • Dividend Yield
  • OXLC 18.86%
  • DNTH N/A
  • EPS Growth
  • OXLC N/A
  • DNTH N/A
  • EPS
  • OXLC 1.20
  • DNTH N/A
  • Revenue
  • OXLC $130,145,365.00
  • DNTH $3,078,000.00
  • Revenue This Year
  • OXLC $136.15
  • DNTH N/A
  • Revenue Next Year
  • OXLC $5.51
  • DNTH N/A
  • P/E Ratio
  • OXLC $4.24
  • DNTH N/A
  • Revenue Growth
  • OXLC N/A
  • DNTH N/A
  • 52 Week Low
  • OXLC $4.41
  • DNTH $13.37
  • 52 Week High
  • OXLC $5.70
  • DNTH $40.16
  • Technical
  • Relative Strength Index (RSI)
  • OXLC 48.56
  • DNTH 66.85
  • Support Level
  • OXLC $14.87
  • DNTH $32.56
  • Resistance Level
  • OXLC $15.32
  • DNTH $37.50
  • Average True Range (ATR)
  • OXLC 0.28
  • DNTH 1.80
  • MACD
  • OXLC -0.10
  • DNTH 0.38
  • Stochastic Oscillator
  • OXLC 28.47
  • DNTH 95.75

About OXLC Oxford Lane Capital Corp.

Oxford Lane Capital Corp is a non-diversified closed-end management investment company. The fund's investment objective is to maximize its portfolio's risk-adjusted total return over its investment horizon. Its current focus is to seek that return by investing in equity and junior tranches of CLO(collateralized loan obligation) vehicles, which are collateralized by a diverse portfolio of senior loans, and which generally have little to no exposure to real estate loans, mortgage loans or pools of consumer-based debt, such as credit card receivables or auto loans. Its investment plan also includes investing in warehouse facilities, which are financing structures intended to aggregate senior loans that may be used to form the basis of a CLO vehicle.

About DNTH Dianthus Therapeutics Inc.

Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Share on Social Networks: